VIRX
Viracta Therapeutics, Inc.—
New fund stakes
0
Q4 2024 13F · 0 exits
Price
Daily candles with volume.
No data for this timeframe.
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q4 2024: 1 added (0 new), 3 trimmed or exited.
Who's buying
13F· Q4 20240
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| VANGUARD GROUP INC | TRIM | $46.6K |
| UBS Group AG | DOUBLED | $15.0K |
| HRT FINANCIAL LP | TRIM | $13.0K |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | $180.00 |
| MORGAN STANLEY | NEAR_EXIT | $7.1K |
| ROYAL BANK OF CANADA | DOUBLED | $5.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Dec 2024Recent actions
| Date | Firm | Rating |
|---|---|---|
| Dec 27, 2024 | Rodman & Renshaw DOWNGRADE | Neutral |
| Nov 14, 2024 | RBC Capital MAINTAIN | Outperform |
| Aug 16, 2024 | Leerink Partners DOWNGRADE | Market Perform |
| Aug 15, 2024 | RBC Capital MAINTAIN | Outperform |
| May 23, 2024 | Oppenheimer MAINTAIN | Outperform |
| Apr 17, 2024 | Oppenheimer MAINTAIN | Outperform |
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Dec 31, 2024 Inst.
VANGUARD GROUP INC — TRIM
289,174 shares ($46.6K)
Dec 31, 2024 Inst.
UBS Group AG — DOUBLED
93,177 shares ($15.0K)